Can I mix insulin glargine with other insulins?

No. Insulin glargine must never be mixed with any other insulin in the same syringe. Its pH formulation (acidic) would alter the pharmacokinetics of both insulins and it would lose its long-acting properties. Use separate injections for basal and bolus insulins.

What should I do if I have a low blood sugar (hypoglycemia)?

Treat immediately with 15g of fast-acting carbohydrate: 4 glucose tablets, 4 oz juice, 4 oz regular soda (not diet), or glucose gel. Wait 15 minutes and recheck. If still below 70 mg/dL, repeat. Eat a snack with protein and carbohydrate if the next meal is more than an hour away. If you cannot treat yourself, call 911. Keep glucagon (GlucaGen or Baqsimi) available and ensure someone knows how to use it.

Does insulin glargine cause weight gain?

Yes. Starting insulin therapy causes weight gain in most patients — typically 2-4 kg. This occurs because better glucose control reduces glucose loss in urine, and insulin is an anabolic hormone that promotes fat and protein storage. Managing carbohydrate intake and maintaining physical activity helps minimize weight gain.

Is insulin glargine the same as Lantus, Basaglar, and Toujeo?

They are related but not identical. Lantus (originator) and Basaglar (biosimilar) are equivalent 100 units/mL formulations. Toujeo is a higher-concentration formulation (300 units/mL), providing more stable 24-hour coverage with less injection volume — useful for patients needing larger doses. Do not switch between these without prescriber guidance, as dose adjustments may be needed.

What to Expect When Starting Insulin glargine

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Insulin glargine (Lantus, Basaglar, Toujeo) is a long-acting basal insulin analog that provides steady, 24-hour background insulin coverage without peaks. It is used to treat type 1 and type 2 diabetes. Unlike NPH insulin, it has a flat action profile with no pronounced peak, reducing nocturnal hypoglycemia risk. Starting insulin glargine requires education on injection technique, hypoglycemia recognition, and dose adjustment.

Week-by-week timeline

Day 1-3

First Injections

Insulin glargine is injected subcutaneously once daily, typically at the same time each day (bedtime or morning — choose one and stay consistent). The starting dose for type 2 diabetes is typically 10 units or 0.1-0.2 units/kg. Inject into the abdomen, thigh, or upper arm — rotate sites within the same area. Mild stinging or burning at the injection site is normal.

Week 1-2

Initial Dose Finding

Fasting morning blood glucose is the key target for insulin glargine dose titration. The '2-2-2' or '3-3-3' rule is common: if fasting glucose is above target for 3 consecutive days, increase the dose by 2 units. Blood glucose should be checked daily. Carry glucose tablets or juice at all times for hypoglycemia.

Week 2-4

Dose Titration

Insulin doses are increased gradually (typically by 2 units every 3 days) until fasting glucose is consistently at goal (70-130 mg/dL for most adults). Avoid large dose jumps to prevent hypoglycemia. Your prescriber or diabetes educator will help guide titration.

Month 1

Stable Baseline Coverage

A stable basal insulin dose providing consistent fasting glucose control is the goal. HbA1c will begin to fall measurably over 3 months. If fasting glucose is controlled but post-meal glucose remains high, mealtime (bolus) insulin or other agents may be added.

Month 2-3

Ongoing Optimization

HbA1c checked at 3 months reflects the improvement in overall glycemic control since starting insulin. Discuss with your prescriber whether dose adjustments, additional medications, or mealtime insulin are needed. Stable patients settle into a predictable routine.

When to call your doctor

Contact your healthcare provider if you experience:

Symptomatic hypoglycemia: shakiness, sweating, rapid heart rate, confusion, dizziness, hunger — treat immediately with 15g fast-acting carbohydrate (glucose tablets, juice, regular soda)
Severe hypoglycemia: unable to self-treat, loss of consciousness, or seizure — call 911 and use glucagon if available
Injection site infection: redness, warmth, swelling, pus
Allergic reaction: generalized rash, hives, difficulty breathing
Hypoglycemia at unusual times or severely low levels (below 54 mg/dL) — dose may be too high
Signs of diabetic ketoacidosis if type 1: nausea, vomiting, abdominal pain, fruity breath, rapid breathing

Tips for getting started

Inject insulin glargine at the same time each day for predictable coverage — bedtime is common for type 2 patients to minimize next-morning fasting glucose. Never mix insulin glargine in the same syringe with other insulins — it loses its long-acting properties. Rotate injection sites within an area (same region, not same spot) to prevent lipohypertrophy (lumpy tissue from injecting the same spot). Keep insulin at room temperature for up to 28 days after opening — cold insulin stings more. Dispose of needles safely in an approved sharps container. Always carry fast-acting glucose (glucose tablets, juice) for hypoglycemia emergencies.

Frequently asked questions

More about Insulin glargine

Insulin glargine drug guideSide effects, dosage, interactions, and more Insulin glargine vs Insulin lisproCompare these medications Insulin glargine & PioglitazoneInteraction details Semaglutide (Ozempic) & Insulin glargineInteraction details Semaglutide (Rybelsus) & Insulin glargineInteraction details

References

[Regulatory] FDA Label: Lantus (insulin glargine) Injection https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf Accessed 2026-03-01.
[Regulatory] NIH MedlinePlus: Insulin Glargine Injection https://medlineplus.gov/druginfo/meds/a600027.html Accessed 2026-03-01.
[Regulatory] ADA Standards of Care: Insulin Therapy https://diabetesjournals.org/care/issue/47/Supplement_1 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026